Skip to main content

Main menu

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics

User menu

  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Anticancer Research
  • Other Publications
    • Anticancer Research
    • In Vivo
    • Cancer Genomics & Proteomics
  • Register
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Anticancer Research

Advanced Search

  • Home
  • Current Issue
  • Archive
  • Info for
    • Authors
    • Editorial Policies
    • Subscribers
    • Advertisers
    • Editorial Board
    • Special Issues
  • Journal Metrics
  • Other Publications
    • In Vivo
    • Cancer Genomics & Proteomics
    • Cancer Diagnosis & Prognosis
  • More
    • IIAR
    • Conferences
    • 2008 Nobel Laureates
  • About Us
    • General Policy
    • Contact
  • Visit us on Facebook
  • Follow us on Linkedin
Research ArticleExperimental Studies

Influence of Gefitinib and Erlotinib on Apoptosis and c-MYC Expression in H23 Lung Cancer Cells

MITSUHIRO SUENAGA, MASATATSU YAMAMOTO, SHO TABATA, SUSUMU ITAKURA, MASAAKI MIYATA, SHUICHI HAMASAKI and TATSUHIKO FURUKAWA
Anticancer Research April 2013, 33 (4) 1547-1554;
MITSUHIRO SUENAGA
1Department of Cardiovascular, Respiratory and Metabolic Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASATATSU YAMAMOTO
2Department of Molecular Oncology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHO TABATA
2Department of Molecular Oncology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SUSUMU ITAKURA
1Department of Cardiovascular, Respiratory and Metabolic Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
MASAAKI MIYATA
1Department of Cardiovascular, Respiratory and Metabolic Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
SHUICHI HAMASAKI
1Department of Cardiovascular, Respiratory and Metabolic Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
TATSUHIKO FURUKAWA
2Department of Molecular Oncology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: furukawa{at}m3.kufm.kagoshima-u.ac.jp
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Information

vol. 33 no. 4 1547-1554
PMID 
23564796

Published By 
International Institute of Anticancer Research
Print ISSN 
0250-7005
Online ISSN 
1791-7530
History 
  • Received January 8, 2013
  • Revision received February 20, 2013
  • Accepted February 21, 2013
  • Published online April 6, 2013.

Copyright & Usage 
Copyright© 2013 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved

Author Information

  1. MITSUHIRO SUENAGA1,
  2. MASATATSU YAMAMOTO2,
  3. SHO TABATA2,
  4. SUSUMU ITAKURA1,
  5. MASAAKI MIYATA1,
  6. SHUICHI HAMASAKI1 and
  7. TATSUHIKO FURUKAWA2⇑
  1. 1Department of Cardiovascular, Respiratory and Metabolic Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
  2. 2Department of Molecular Oncology, Graduate School of Medical and Dental Sciences, Kagoshima University, Kagoshima, Japan
  1. Correspondence to: Tatsuhiko Furukawa, Department of Molecular Oncology, Graduate School of Medical and Dental Sciences, Kagoshima University, 8-35-1 Sakuragaoka, Kagoshima 890-8544, Japan. Tel: +81 992755490, Fax: +81 992659687, e-mail: furukawa{at}m3.kufm.kagoshima-u.ac.jp
View Full Text

Statistics from Altmetric.com

Cited By...

  • 6 Citations
  • Citations
  • Google Scholar

This article has not yet been cited by articles in journals that are participating in Crossref Cited-by Linking.

PreviousNext
Back to top

In this issue

Anticancer Research
Vol. 33, Issue 4
April 2013
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Back Matter (PDF)
  • Ed Board (PDF)
  • Front Matter (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Anticancer Research.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Influence of Gefitinib and Erlotinib on Apoptosis and c-MYC Expression in H23 Lung Cancer Cells
(Your Name) has sent you a message from Anticancer Research
(Your Name) thought you would like to see the Anticancer Research web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
5 + 4 =
Solve this simple math problem and enter the result. E.g. for 1+3, enter 4.
Citation Tools
Influence of Gefitinib and Erlotinib on Apoptosis and c-MYC Expression in H23 Lung Cancer Cells
MITSUHIRO SUENAGA, MASATATSU YAMAMOTO, SHO TABATA, SUSUMU ITAKURA, MASAAKI MIYATA, SHUICHI HAMASAKI, TATSUHIKO FURUKAWA
Anticancer Research Apr 2013, 33 (4) 1547-1554;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Reprints and Permissions
Share
Influence of Gefitinib and Erlotinib on Apoptosis and c-MYC Expression in H23 Lung Cancer Cells
MITSUHIRO SUENAGA, MASATATSU YAMAMOTO, SHO TABATA, SUSUMU ITAKURA, MASAAKI MIYATA, SHUICHI HAMASAKI, TATSUHIKO FURUKAWA
Anticancer Research Apr 2013, 33 (4) 1547-1554;
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Materials and Methods
    • Results
    • Discussion
    • References
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • IBP1 Represses the Migration and Invasion of Hepatocellular Carcinoma Cells by Inhibiting SOCE-dependent Formation of Neutrophil Extracellular Traps by Targeting the Akt Pathway
  • Proinsulin Promotes Tumor Development in the PANC-1 Pancreatic Adenocarcinoma Cell Line
  • Metformin Induces PARP1-mediated Cell Death in NPC/HK1 Human Nasopharyngeal Carcinoma Cells
Show more Experimental Studies

Keywords

  • gefitinib
  • erlotinib
  • H23 cells
  • apoptosis
  • cell cycle arrest
  • c-MYC
Anticancer Research

© 2026 Anticancer Research

Powered by HighWire